18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: A comparative study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 9, 2011, Pages 1607-1619

  Chan, Sheng Chieh ^a   Wang, Hung Ming ^a   Yen, Tzu Chen ^a   Lin, Chien Yu ^a,b   Chin, Shy Chyi ^a   Liao, Chun Ta ^a   Wai, Yau Yau ^a   Wang, Jiun Jie ^a   Ng, Shu Hang ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Distant metastasis; FDG; Head and neck cancer; Hypopharyngeal carcinoma; MRI; Oropharyngeal carcinoma; PET; Second primary cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; COLON CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISTANT METASTASIS; ESOPHAGUS CANCER; FEASIBILITY STUDY; FEMALE; HUMAN; HYPOPHARYNX CARCINOMA; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CANCER; OROPHARYNX CARCINOMA; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SECOND CANCER; SENSITIVITY ANALYSIS; TONGUE CANCER; TONSIL CANCER; WHOLE BODY MRI; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; HYPOPHARYNX TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX TUMOR; PATHOLOGY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; WHOLE BODY IMAGING;

BIOLOGICAL TRANSPORT; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; OROPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; WHOLE BODY IMAGING;

EID: 80455174058     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1824-y     Document Type: Article

References (43)

1. Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol. 2001;19:1358-62. (Pubitemid 32202541)
2. Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:202-7. (Pubitemid 32620169)
3. Goodwin WJ. Distant metastases from oropharyngeal cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:222-3. (Pubitemid 32620173)
4. Brochet F, Bairati I, Roy J, Gelinas M, Nabid A, Tetu B, et al. Incidence and risk factors of second primary cancers in patients treated for primary pharyngeal cancer. Bull Cancer Radiother. 1996;83:8-11. (Pubitemid 26128297)
5. Chuang SC, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Kliewer EV, et al. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer. 2008;123:2390-6.
6. Cohan DM, Popat S, Kaplan SE, Rigual N, Loree T, Hicks Jr WL. Oropharyngeal cancer: current understanding and management. Curr Opin Otolaryngol Head Neck Surg. 2009;17:88-94.
7. Lin DT, Cohen SM, Coppit GL, Burkey BB. Squamous cell carcinoma of the oropharynx and hypopharynx. Otolaryngol Clin North Am. 2005;38:59-74. (Pubitemid 40092928)
8. Brouwer J, Senft A, de Bree R, Comans EF, Golding RP, Castelijns JA, et al. Screening for distant metastases in patients with head and neck cancer: is there a role for (18) FDG-PET? Oral Oncol. 2006;42:275-80. (Pubitemid 43246759)
9. Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med. 2004;34:180-97. (Pubitemid 38887174)
10. Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol. 2008;97:649-52. (Pubitemid 351812964)
11. Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233:139-48. (Pubitemid 39280968)
12. Schick F, Whole-body MRI. at high field: technical limits and clinical potential. Eur Radiol. 2005;15:946-59. (Pubitemid 41166727)
13. Walker RE, Eustace SJ. Whole-body magnetic resonance imaging: techniques, clinical indications, and future applications. Semin Musculoskelet Radiol. 2001;5:5-20. (Pubitemid 32238551)
14. Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ. A comparison of whole-body MRI and CT for the staging of lymphoma. AJR Am J Roentgenol. 2005;185:711-6.
15. Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging. 2007;26:498-509. (Pubitemid 350194569)
16. Squillaci E, Manenti G, Mancino S, Ciccio C, Calabria F, Danieli R, et al. Staging of colon cancer: whole-body MRI vs. wholebody PET-CT - initial clinical experience. Abdom Imaging. 2008;33:676-88.
17. Lo GG, Ai V, Au-Yeung KM, Chan JK, Li KW, Chien D. Magnetic resonance whole body imaging at 3 Tesla: feasibility and findings in a cohort of asymptomatic medical doctors. Hong Kong Med J. 2008;14:90-6.
18. Schmidt GP, Wintersperger B, Graser A, Baur-Melnyk A, Reiser MF, Schoenberg SO. High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: A comparative study. Invest Radiol. 2007;42:449-59. (Pubitemid 46788746)
19. Willinek WA, Schild HH. Clinical advantages of 3.0T MRI over 1.5T. Eur J Radiol. 2008;65:2.
20. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and wholebody MRI for tumor staging in oncology. JAMA. 2003;290:3199-206. (Pubitemid 38020681)
21. Ng SH, Chan SC, Yen TC, Chang JT, Liao CT, Ko SF, et al. (2009) Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. Eur Radiol. 2009;19:2965-76
22. Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer. 2007;43:557-64. (Pubitemid 46177588)
23. Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Nonsmall cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248:632-42.
24. Ng SH, Chan SC, Liao CT, Chang JT, Ko SF, Wang HM, et al. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18) F-FDG PET and extended-field multi-detector row CT. Neuroradiology. 2008;50:969-79.
25. Ng SH, Yen TC, Chang JT, Chan SC, Ko SF, Wang HM, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol. 2006;24:4371-6. (Pubitemid 46646246)
26. Yeh DW, Lee KS, Han J, Yi CA, Lee HY, Chung MJ, et al. Mediastinal nodes in patients with non-small cell lung cancer: MRI findings with PET/CT and pathologic correlation. AJR Am J Roentgenol. 2009;193:813-21.
27. Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F] fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: A multicenter prospective study. J Clin Oncol. 2010;28:1190-5.
28. Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: A prospective study of 124 patients with histologic correlation. J Nucl Med. 2005;46:1136-43. (Pubitemid 43741075)
29. Yoon DY, Hwang HS, Chang SK, Rho YS, Ahn HY, Kim JH, et al. CT, MR, US, 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2009;19:634-42.
30. Xu GZ, Zhu XD, Li MY. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: A meta-analysis. Head Neck. 2011;33:87-94
31. Haerle SK, Strobel K, Hany TF, Sidler D, Stoeckli SJ. (18) F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck. 2010;32:319-25.
32. Calhoun KH, Fulmer P, Weiss R, Hokanson JA. Distant metastases from head and neck squamous cell carcinomas. Laryngoscope. 1994;104:1199-205. (Pubitemid 24307889)
33. Lauenstein TC, Goehde SC, Herborn CU, Treder W, Ruehm SG, Debatin JF, et al. Three-dimensional volumetric interpolated breath-hold MR imaging for whole-body tumor staging in less than 15 minutes: A feasibility study. AJR Am J Roentgenol. 2002;179:445-9. (Pubitemid 34785650)
34. Frericks BB, Meyer BC, Martus P, Wendt M, Wolf KJ, Wacker F. MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to thoracic multidetector computed tomography (MDCT). J Magn Reson Imaging. 2008;27:538-45. (Pubitemid 351354738)
35. Devaraj A, Cook GJ, Hansell DM. PET/CT in non-small cell lung cancer staging - promises and problems. Clin Radiol. 2007;62:97-108. (Pubitemid 46024214)
36. Bakheet SM, Amin T, Alia AG, Kuzo R, Powe J. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med. 1999;24:995-7.
37. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghaziel A, Lehmann W, et al. Standardized uptake value of 2-[(18)F]fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398-404. (Pubitemid 34177448)
38. Chan SC, Chang JT, Wang HM, Lin CY, Ng SH, Fan KH, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol. 2009;45:52-8.
39. Inokuchi H, Kodaira T, Tachibana H, Nakamura T, Tomita N, Nakahara R, et al. Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys. 2011;79:747-55
40. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys. 2009;73:764-71.
41. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-84. (Pubitemid 350190758)
42. Jaffe TA, Yoshizumi TT, Toncheva G, Anderson-Evans C, Lowry C, Miller CM, et al. Radiation dose for body CT protocols: variability of scanners at one institution. AJR Am J Roentgenol. 2009;193:1141-7.
43. Leide-Svegborn S. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. Radiat Prot Dosim. 2010;139:208-13.